EWTX Edgewise Therapeutics Inc

Price (delayed)

$22.86

Market cap

$2.14B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.55

Enterprise value

$2.11B

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. ...

Highlights
The quick ratio has soared by 92% from the previous quarter and by 41% YoY
Edgewise Therapeutics's equity has soared by 68% from the previous quarter and by 63% YoY
The net income is down by 40% year-on-year and by 6% since the previous quarter
The EPS fell by 17% YoY

Key stats

What are the main financial stats of EWTX
Market
Shares outstanding
93.4M
Market cap
$2.14B
Enterprise value
$2.11B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.98
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$105.85M
EBITDA
-$103.83M
Free cash flow
-$99.39M
Per share
EPS
-$1.55
Free cash flow per share
-$1.14
Book value per share
$5.75
Revenue per share
$0
TBVPS
$6.32
Balance sheet
Total assets
$553.81M
Total liabilities
$18.87M
Debt
$5.25M
Equity
$534.94M
Working capital
$526.83M
Liquidity
Debt to equity
0.01
Current ratio
37.08
Quick ratio
36.49
Net debt/EBITDA
0.24
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-27.6%
Return on equity
-29.1%
Return on invested capital
-32.2%
Return on capital employed
-19.6%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EWTX stock price

How has the Edgewise Therapeutics stock price performed over time
Intraday
1.96%
1 week
9.27%
1 month
30.55%
1 year
216.62%
YTD
108.96%
QTD
26.93%

Financial performance

How have Edgewise Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$123.41M
Net income
-$105.85M
Gross margin
N/A
Net margin
N/A
The operating income has declined by 50% year-on-year and by 8% since the previous quarter
The net income is down by 40% year-on-year and by 6% since the previous quarter

Growth

What is Edgewise Therapeutics's growth rate over time

Valuation

What is Edgewise Therapeutics stock price valuation
P/E
N/A
P/B
3.98
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS fell by 17% YoY
The P/B is 95% more than the last 4 quarters average of 2.0
Edgewise Therapeutics's equity has soared by 68% from the previous quarter and by 63% YoY

Efficiency

How efficient is Edgewise Therapeutics business performance
EWTX's ROA is down by 23% year-on-year but it is up by 9% since the previous quarter
Edgewise Therapeutics's ROE has decreased by 23% YoY but it has increased by 9% from the previous quarter
EWTX's ROIC is down by 18% YoY but it is up by 12% QoQ

Dividends

What is EWTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EWTX.

Financial health

How did Edgewise Therapeutics financials performed over time
The quick ratio has soared by 92% from the previous quarter and by 41% YoY
EWTX's current ratio has surged by 90% since the previous quarter and by 41% year-on-year
Edgewise Therapeutics's debt is 99% less than its equity
Edgewise Therapeutics's equity has soared by 68% from the previous quarter and by 63% YoY
Edgewise Therapeutics's debt to equity has shrunk by 50% QoQ and by 50% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.